Denali Therapeutics Inc. DNLI Business Segments
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Total collaboration revenue by Product | ||||||
| Milestone Payment | $10M0.0% | $10M0.0% | $10M0.0% | $10M0.0% | $10M0.0% | |
| Milestone Triggered | $100M0.0% | $100M+33.3% | $100M+100% | $100M+300% | $100M— | |
| Option Fee Payment | $10M+100% | $8.75M+75.0% | $7.5M+50.0% | $6.25M+25.0% | $5M0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Denali Therapeutics Inc. break its business down?
- Denali Therapeutics Inc. (DNLI) reports total collaboration revenue by product across 3 parts — Milestone Payment, Milestone Triggered and Option Fee Payment. Each is extracted from the segment footnotes and tracked over time.
- Where does Denali Therapeutics Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Denali Therapeutics Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.